ASH 2022 Conference Coverage

 

Lymphoma
05:34

ASH 2022 Conference Coverage

ASH 2022 Patient Reports Outcomes & Health-Related Quality of Life From the OUTREACH Study: Lisocabtagene Maraleucel in Patients With R/R LBCL Treated as Outpatients/Inpatients in the Community/Non-University Setting

FEATURING Yuliya Linhares
  • 39 views
  • April 3, 2023
  • 1
05:08

ASH 2022 Conference Coverage

ASH 2022 Results From the Phase 2 OUTREACH Study: Lisocabtagene Maraleucel Administered as Outpatient/Inpatient Treatment in the Community/Non-University Setting in Patients With R/R LBCL

FEATURING Yuliya Linhares
  • 30 views
  • April 3, 2023
  • 1
07:06

ASH 2022 Conference Coverage

ASH 2022 Phase 3 ZUMA-7 Study: Outcomes of Subsequent Anti-Lymphoma Therapies in Pts With LBCL Treated With Axi-Cel or SoC in the 2L

FEATURING Armin Ghobadi
  • 92 views
  • January 28, 2023
06:31

ASH 2022 Conference Coverage

ASH 2022 Results From a Prespecified Analysis of the Pivotal Phase II Study ELM-2: Odronextamab in Patients With R/R FL Grade 1-3a

FEATURING Deepa Jagadeesh
  • 43 views
  • January 27, 2023
12:39

ASH 2022 Conference Coverage

ASH 2022 Five-Year Survival Results From REMoDL-B: Outcomes in DLBCL Molecular Subgroups From the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

FEATURING Andrew Davies
  • 134 views
  • January 13, 2023
08:04

ASH 2022 Conference Coverage

ASH 2022 Results from BRUIN: A Phase 1/2 Study of Pirtobrutinib, a Highly Selective, Non-Covalent BTKi in Richter Transformation

FEATURING Nirav Shah
  • 58 views
  • January 11, 2023
08:54

ASH 2022 Conference Coverage

ECOG-ACRIN E1411: A Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab Based Induction Followed by Rituximab ± Lenalidomide Consolidation for MCL

FEATURING Mitchell Smith
  • 114 views
  • January 4, 2023
  • 1
04:07

ASH 2022 Conference Coverage

ASH 2022 Anti-CD19 CAR T-Cell Therapy for Patients With Richter Syndrome: LYSA Study From the DESCAR-T Registry

FEATURING Romain Guieze
  • 29 views
  • January 4, 2023
10:17

ASH 2022 Conference Coverage

ASH 2022 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in R/R FL: Analysis of Safety, Efficacy, and MRD

FEATURING Christopher J. Melani
  • 74 views
  • January 4, 2023
27:09

ASH 2022 Conference Coverage

ASH 2022: What Is Complete HLA Match in 2022?

FEATURING Stephen Spellman
  • 193 views
  • January 4, 2023
  • 2
12:50

ASH 2022 Conference Coverage

ASH 2022 on Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia

FEATURING Jorge Castillo
  • 64 views
  • December 22, 2022
  • 1
07:49

ASH 2022 Conference Coverage

ASH 2022 High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

FEATURING Narendranath Epperla
  • 162 views
  • December 22, 2022
06:12

ASH 2022 Conference Coverage

ASH 2022 Phase 1b/2a Study Results From Dose-Escalation: AZD4573 (CDK9i) & Acalabrutinib in R/R DLBCL

FEATURING Paolo Strati
  • 33 views
  • December 22, 2022
14:28

ASH 2022 Conference Coverage

ASH 2022 CNS Prophylaxis in Aggressive B-Cell Lymphoma

FEATURING Kate Cwynarski
  • 552 views
  • December 21, 2022
  • 6
06:35

ASH 2022 Conference Coverage

Results From a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for MCL

FEATURING Nirav Shah
  • 143 views
  • December 21, 2022
10:36

ASH 2022 Conference Coverage

The CAR-HEMATOTOX Score Identifies Patients at High Risk for Hematological Toxicity, Infections, and Poor Clinical Outcomes Following Brexucabtagene Autoleucel in R/R MCL

FEATURING Kai Rejeski
  • 117 views
  • December 21, 2022
05:04

ASH 2022 Conference Coverage

ASH 2022 Phase III SUNMO Trial: Evaluating the Efficacy & Safety of Mosunetuzumab + Polatuzumab Vedotin vs. Rituximab + Gemcitabine & Oxaliplatin in R/R Aggressive B-Cell NHL

FEATURING Jason Westin
  • 299 views
  • December 19, 2022
  • 1
08:34

ASH 2022 Conference Coverage

ASH 2022: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-Cell Malignancies

FEATURING Mazyar Shadman
  • 145 views
  • December 19, 2022
08:02

ASH 2022 Conference Coverage

ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil as the New Standard for GVHD Prophylaxis in Reduced Intensity Conditioning

FEATURING Shernan Holtan
  • 352 views
  • December 19, 2022
  • 1
08:15

ASH 2022 Conference Coverage

ASH 2022: Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated R/R Mantle Cell Lymphoma

FEATURING Tycel Phillips
  • 196 views
  • December 16, 2022
06:01

ASH 2022 Conference Coverage

ASH 2022 Outcomes of R/R Double Hit Lymphoma: A Multicenter Observational Cohort

FEATURING Sanjal Desai
  • 541 views
  • December 16, 2022
  • 1
12:52

ASH 2022 Conference Coverage

ASH 2022 on the Phase Ib/II Study of Polatuzumab Vedotin + Obinutuzumab & Lenalidomide in R/R Follicular Lymphoma: Final Analysis and PFS Update

FEATURING Catherine Diefenbach
  • 50 views
  • December 16, 2022
05:55

ASH 2022 Conference Coverage

ASH 2022 Phase 3 ZUMA-7 Trial Updates: Association of Metabolic Tumor Volume and Clinical Outcomes in 2L R/R LBCL Following Axicabtagene Ciloleucel vs. SoC Therapy

FEATURING Frederick L. Locke
  • 83 views
  • December 16, 2022
  • 1
07:02

ASH 2022 Conference Coverage

ASH 2022 Results of the Phase II Radvax Trial: Low-Dose RT With Nivo in Patients With R/R Hodgkin Lymphoma

FEATURING Michael LaRiviere
  • 50 views
  • December 16, 2022